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Background: Multidrug resistance (MDR) of cancers can be circumvented by inducing 
  programmed cell death, which is known as apoptosis. Mitochondria play a crucial role in 
  apoptosis. Mitochondria-specific therapy would provide an efficient strategy for treating resis-
tant cancers.
Design and methods: A strategy was proposed here to overcome MDR by designing cancer 
mitochondria-specific drug-loaded liposomes, namely, antiresistant epirubicin mitosomes, aimed 
at treating resistant leukemia by targeting mitochondria. Evaluations were performed on human 
chronic leukemia K562, MDR K562/ADR cells, and female BALB/c nude mice xenografted 
with MDR K562/ADR cells. The liposomes were characterized through assays of cytotoxicity, 
mitochondrial targeting, caspase-9 and caspase-3, antitumor activities, and TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labeling) analysis.
Results: The average size of antiresistant epirubicin mitosomes was in the range of 105–115 nm. 
Antiresistant epirubicin mitosomes were effective in inhibiting proliferation of MDR K562/ADR 
cells in vitro and selectively accumulated into the mitochondria. Caspase-9 and caspase-3 activity 
was increased after applying antiresistant epirubicin mitosomes. In xenografted resistant MDR 
K562/ADR tumor in nude mice, antiresistant tumor effect of antiresistant epirubicin mitosomes 
was evidently observed. Apoptotic inducing effects by antiresistant epirubicin mitosomes were 
noticeably evidenced via mitochondrial pathway.
Conclusions: Antiresistant epirubicin mitosomes had significant inhibitory effect against 
resistant leukemia in vitro and in vivo, hence providing a promising strategy for improving 
therapeutic efficacy in resistant human leukemia.
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Introduction
Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy, 
and has been evidenced in a variety of cancers, including leukemia and breast,   ovarian, 
lung, and lower gastrointestinal tract cancers.1 The major mechanisms of MDR could 
be derived from acquired and/or intrinsic factors.2 Acquired resistance develops   during 
chemotherapy, resulting in the following outcomes: (1) less drug accumulation in 
cancer cells due to the efflux of drugs by overexpression of adenosine triphosphate 
(ATP)-binding cassette (ABC) transporters; (2) an enhanced drug-detoxifying func-
tion of cancer cells due to the enhanced deoxyribonucleic acid (DNA) repair ability 
and the increased activity of cytochrome P-450; and (3) decreased sensitivity of 
apoptosis due to the alteration of caspases.3 In contrast, intrinsic resistance already 
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(2) the genetic/epigenetic alternations such as activation of 
oncogenes and inactivation of tumor suppressor genes, or (3) 
the alternation of the apoptosis pathways.4 Most likely, the 
MDR of leukemia is due to the intrinsic resistance.
Mitochondria are the powerhouses of cells, and the process 
of creating cell energy is known as cellular   respiration. Most 
chemical reactions involved in cellular respiration happen in 
the mitochondria. The process by which   mitochondria syn-
thesize ATP by oxidative phosphorylation via the respiratory 
chain creates a transmembrane electrochemical gradient.5 The 
membrane potential of mitochondria in vitro is estimated 
to be in the range of 180–200 mV ,6 while the membrane 
potential of mitochondria in living cells and organisms is 
lower (130–150 mV) due to metabolic processes such as ATP 
synthesis and ion transport.7 This feature makes it possible to 
accumulate organic cations into mitochondria. Sufficient lipo-
philicity and delocalization of the positive charge are the pre-
requisites for mitochondrial accumulation of organic   cations 
in response to the mitochondrial membrane potential.8
Mitochondria are also known to play a role in pro-
grammed cell death via apoptosis.9 Generally speaking, there 
are two semi-interdependent routes leading to apoptosis.10 
One route involves the ligand binding to death receptors at 
the cell surface,11 while another involves mitochondria.12 
In the latter route, apoptotic inducer induces an increase 
in the permeability of the outer membrane, causing the 
release of cytochrome c,13 and therefore triggering apoptosis. 
  Cytochrome c may be released from mitochondria to the cyto-
sol through Bax/Bak channels, permeability transition (PT) 
pores, or damaged mitochondrial membrane.13 Meanwhile, 
the activated caspase family leads to a cascade of events in the 
cytosol,14 eventually resulting in partial self-digestion of cells. 
There are two kinds of apoptotic gene-encoded proteins on 
the outer membrane of the mitochondria. One is pro-apoptotic 
gene-encoded proteins such as Bid and Bax, and the other 
one is apoptotic suppressing gene-encoded proteins such as 
Bcl-2 and Bcl-XL.15–18 These proteins play important roles in 
the process of apoptosis. As mitochondria play a major step-
limiting role in apoptosis of cells,12 it is necessary to deliver 
drugs to the mitochondria in order to activate pro-apoptotic 
genes or inhibit apoptotic suppressing genes.
Proposed here is a new strategy to circumvent the 
MDR of leukemia by designing cancer cell mitochondria-
specific drug-loaded liposomes, ie, antiresistant epirubi-
cin   mitosomes. In the lipid-based mitosomes, epirubicin 
was encapsulated into the vesicle as an anticancer agent, 
  amlodipine was simultaneously incorporated into the vesicle 
as an apoptotic inducer of leukemia, and dequalinium was 
inserted into the lipid bilayer membrane of the mitosome as 
a mitochondrial targeting molecule. Antiresistant epirubicin 
mitosomes were developed for the following purposes: (1) the 
resistant/nonresistant leukemia cells could be killed directly 
by antiresistant epirubicin mitosomes; (2) the mitochondrial 
genes could be regulated by apoptotic inducer amlodipine, 
which was selectively delivered to the mitochondria by the 
antiresistant epirubicin mitosomes.
Epirubicin is an anthracycline drug used for   chemotherapy. 
It acts by intercalating with DNA strands and triggering 
DNA cleavage via topoisomerase II, resulting in death 
of cancer cells. In addition, epirubicin generates free 
  radicals that cause cell and DNA damage.19   Amlodipine is 
a dihydropyridine Ca2+ channel blocker used for   treating 
hypertension. In the present study, amlodipine was used 
as a pro-apoptotic inducer of leukemia because it was 
  previously found that amlodipine was able to potentiate the 
apoptosis of leukemia cells.20 Dequalinium is a   dicationic 
compound resembling “bola”-form electrolytes, and a 
symmetrical molecule with two charge centers separated 
at a relatively large distance. It is able to accumulate in the 
mitochondria of living cells in response to mitochondrial 
membrane potential.21,22   Dequalinium was thus modified on 
the mitosomes as a specific ligand for targeting mitochondria 
of leukemia cells.
In the present study, the building of antiresistant epiru-
bicin mitosomes was based on the following hypotheses: 
antiresistant epirubicin mitosomes may enter into the cancer 
cells by phagocytosis and remain as two forms: namely, 
the integrated mitosomes and the ruptured mitosomes. 
The integrated mitosomes can target mitochondria due 
to mitochondrial affinity of dequalinium modified on the 
mitosomes.23 Accordingly, epirubicin and amlodipine may 
activitate the Bax/Bak channel, induce the PT pore opening, 
damage the membrane of mitochondria, and thus result in 
the release of apoptogenic factors like cytochrome c and 
apoptosis-inducing factor (AIF). The degradation of nuclear 
DNA caused by the released AIF is not via the caspase 
pathway. On the contrary, released cytochrome c triggers 
the apoptosis pathway depending on the activating caspase 
family, including binding with apoptosis protease activating 
factor (Apaf)-1 and then stimulating caspase-9. The cleav-
age of caspase-9 initiates a cascade of caspase activation 
like caspase-3, leading to apoptosis of cancer cells.24 On the 
other hand, the mitosomes may induce apoptosis by inhibiting 
Bcl-2 and Bcl-XL in mitochondria. Furthermore, epirubicin International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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from the ruptured mitosomes may intercalate DNA strands in 
the nucleus and directly result in the death of cancer cells.
The objectives of the present study were to prepare the 
antiresistant epirubicin mitosomes and characterize their 
properties on human chronic myelogenous leukemia K562 
and MDR K562/ADR cells in vitro and in vivo.
Design and methods
Preparation of antiresistant epirubicin  
mitosomes
Four types of liposomes were prepared: (1) antiresistant 
epirubicin mitosomes, which were used as the cancer cell 
mitochondria-specific liposomes; (2) antiresistant epirubicin 
liposomes; (3) epirubicin liposomes; and (4) amlodipine 
liposomes. The latter three types of liposomes were used as 
the controls.
Antiresistant epirubicin mitosomes
Egg phosphatidylcholine (EPC), 3β-[N-(N′,N′-
dimethylaminoethane)-carbamoyl] cholesterol hydro-
chloride (DC-cholesterol HCl; Avanti Polar Lipids, 
Alabaster, AL), polyethylene glycol-distearoylphosphos-
phatidyl ethanolamine (PEG2000-DSPE; NOF Corpora-
tion, Tokyo, Japan), and dequalinium (Hangzhou Sanhe 
Chemicals Co, Ltd, Hangzhou, China) (in a 60:25:5:15 µmol 
ratio) were dissolved in methanol in a pear-shaped flask. 
The methanol was evaporated to dryness under vacuum 
with a rotary evaporator, and then the formed lipid film was 
hydrated with 250 mM ammonium sulfate by sonication in 
the water bath for 5 minutes and followed by sonication using 
a probe-type sonicator for 6.8 minutes. The suspensions after 
hydration were successively extruded through polycarbon-
ate membranes (Millipore, Bedford, MA), with pore sizes 
of 400 and 200 nm, three times, respectively. The blank 
liposomes modified with dequalinium were then obtained 
and dialyzed (12,000–14,000 molecular mass cutoff) in 
phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM 
KCl, 8 mM Na2HPO4, and 2 mM KH2PO4, pH 7.4) three 
times (12 hours each time). Epirubicin and amlodipine were 
loaded using an ammonium sulfate gradient loading method, 
as reported previously.20 The blank liposomes modified with 
dequalinium were mixed with an appropriate amount of epi-
rubicin hydrochloride (Nanjing Tianzun Zezhong Chemicals 
Ltd, Jinagsu, China), incubated at 60°C in a water bath, and 
intermittently shaken for 20 minutes. An appropriate amount 
of amlodipine besylate (Beijing Yimin Pharmaceuticals Co, 
Ltd, Beijing, China) was added to the above liposomes, 
further incubated for 10 minutes, producing the antiresistant 
epirubicin mitosomes.
Antiresistant epirubicin liposomes
The antiresistant epirubicin liposomes were prepared using 
the same procedure used to prepare the antiresistant epiru-
bicin mitosomes, excluding the addition of dequalinium in 
the formed lipid membrane.
epirubicin liposomes
The epirubicin liposomes were prepared using the same pro-
cedure used to prepare the antiresistant epirubicin liposomes, 
excluding the addition of amlodipine during drug loading.
Amlodipine liposomes
The amlodipine liposomes were prepared using the same 
procedure used to prepare the antiresistant epirubicin lipo-
somes, excluding the addition of epirubicin during drug 
loading. The incubation duration for loading amlodipine 
was 30 minutes.
characterization of the liposomes
Epirubicin, amlodipine, and dequalinium were measured on 
ODS column (Nucleodur 100-5 C18, 250 mm × 4.6 mm, 
5 µm) by high performance liquid chromatography (HPLC) 
system with ultraviolet detector (Agilent Technologies Inc, 
Cotati, CA). The mobile phase consisted of acetonitrile, 
0.02 M NaH2PO4 and triethylamine (34.0:66.0:0.3, v/v) 
and adjusted to pH 4.0 with phosphoric acid. The detection 
wavelength was set at 240 nm, the flow rate was 1.0 mL/min, 
and the injection volume was 20 µL.
All the liposomes were passed over a Sephadex G-50 
column (Sigma-Aldrich Corporation agent, Beijing, China) 
to remove the unencapsulated epirubicin and amlodipine or 
unmodified dequalinium. The encapsulation efficiency of 
epirubicin or amlodipine was calculated with the formula: 
EE = W encap/Wtotal × 100%, where EE is the encapsulation 
efficiency of epirubicin or amlodipine, Wencap is the mea-
sured amount of epirubicin or amlodipine in the liposome 
suspensions after passing over the column, and Wtotal is the 
measured amount of epirubicin or amlodipine in the equal 
volume of liposome suspensions before passing over the 
column. The modifying efficiency of dequalinium was 
defined as Wdeq per µmol lipids, where Wdeq is the mea-
sured amount of dequalinium on the liposome surface. The 
liposome sample was destroyed and measured by HPLC 
as above.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The particle sizes, polydispersity indexes (PDI), and 
zeta potential values of all liposomes were measured 
with   Zetasizer 3000HSA (Malvern Instruments Ltd, 
  Worcestershire, UK). The antiresistant epirubicin mitosomes 
were stained with 1% uranyl acetate and observed under 
transmission electron microscopy (TEM) (Tecnai G2 20ST, 
FEI Co, Tokyo, Japan).
In-vitro drug release assays of epirubicin and amlodipine 
from all liposomes were performed using the method reported 
previously.25 A volume of 2 mL antiresistant epirubicin 
mitosomes, antiresistant epirubicin liposomes, epirubicin 
liposomes, or amlodipine liposomes was mixed with 2 mL 
of release medium (a mixture of PBS and 10% fetal bovine 
serum [FBS]), and the mixture was then placed into the 
  dialysis tubing. The dialysis tubing was placed into 20.0 mL 
of the release medium, and oscillated with a shaker at a rate 
of 100 times per minute at 37°C. A volume of 0.2 mL release 
medium was sampled at 0, 0.25, 0.50, 1.00, 2.00, 4.00, 8.00, 
12.00, 24.00, and 48.00 hours, followed by immediately add-
ing an equal volume of fresh release medium. The content 
of epirubicin or amlodipine was determined by HPLC as 
above, and the release rate was estimated with the formula: 
RR = (Wi/Wtotal) × 100%, where RR is the drug release rate 
(%), Wi is the measured drug amount of each sample, and 
Wtotal is the total drug amount in an equal volume of liposome 
suspension before performing the release experiment.
cells and cell culture
Human chronic myelogenous leukemia (K562) and multidrug 
resistant human chronic myelogenous leukemia (MDR K562/
ADR cells) (Institute of Hematology, Chinese Academy 
of Medical Sciences and Peking Union Medical College, 
Tianjin, China) were used. The culture medium was pre-
pared with RPMI (Roswell Park Memorial Institute) 1640 
  (Macgene Biotech Co, Ltd, Beijing, China) supplemented 
with 12% heat-inactivated FBS (Invitrogen Corporation, 
New York, NY), antibiotics (penicillin 100 U/mL, strepto-
mycin 100 µg/mL), and 2 mM L-glutamine. The cell culture 
was performed in the incubator (37°C and 5% CO2).
cytotoxicity assay
Microtiter tetrazolium (MTT) assay was performed accord-
ing to a standard MTT-based colorimetric assay.26 Briefly, 
K562, or MDR K562/ADR cells were seeded into a 96-well 
plate at 2 × 104 cells per well, and the cells were cultured in 
the incubator for 24 hours. Fresh medium containing serial 
concentrations of various drug formulations was then added 
into the plate well, including free epirubicin, free amlodipine, 
mixture of various concentrations of free epirubicin and 
amlodipine, epirubicin liposomes, amlodipine liposomes, 
antiresistant epirubicin liposomes, antiresistant epirubicin 
mitosomes, and PBS-loaded mitosomes. Cells incubated in 
medium without any drug were used as controls. After treat-
ment, cells were incubated for 43 hours, and then 20 µL/well 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (5 mg/mL) was added. The plates were incubated for 
an additional 5 hours. The cells were then lyzed using 150 µL 
of sodium dodecyl sulfate (SDS) solution (10 g SDS, 5 mL 
iso-butyl alcohol, 10 mL 0.12 mol/L HCl, deionized water 
made up to 100 mL) and placed overnight in the incubator 
at 37°C. The absorbance values of the lyzed cells were read 
on a microplate reader (Model 680; BIO-RAD Laboratories, 
Tokyo, Japan) at a wavelength of 490 nm. The survival rates 
were calculated with the formula: survival rate (%) = (A490 nm 
treated cells/A490 nm control cells) × 100%, where A490 nm is 
the absorbance value at 490 nm.
Mitochondrial targeting
A confocal laser scanning fluorescent microscope with Leica 
confocal software (Leica, Heidelberg, Germany) was used to 
observe the mitochondrial targeting properties of antiresistant 
epirubicin mitosomes. Briefly, K562 or MDR K562/ADR 
cells were seeded into 6-well plates at 1 × 106 cells per well. 
After incubation for 24 hours, drugs were added, respectively, 
including free epirubicin (10 µM), epirubicin liposomes 
(10 µM), antiresistant epirubicin liposomes (10 µM for 
epirubicin or for amlodipine), and antiresistant epirubicin 
mitosomes (10 µM for epirubicin or for amlodipine). After 
treatment, cells were incubated for 1 hour, and then the 
cells were washed with PBS and stained with MitoTracker® 
Green FM (InvivoGen Corporation agent, Beijing, China). 
Composite images were made by overlapping the images of 
the individual channels.
caspase-9 and -3 activity assays
The activity of caspase-9 was measured using caspase-9 
colorimetric assay kit (Nanjing KeyGen Biotech Co, Ltd, 
Nanjing, China). Briefly, K562 or MDR K562/ADR cells 
were cultured for 24 hours. Drugs were added, respectively, 
including free epirubicin (10 µM), free amlodipine (10 µM), 
epirubicin liposomes (10 µM), antiresistant epirubicin lipo-
somes (10 µM for epirubicin or for amlodipine) and antire-
sistant epirubicin mitosomes (10 µM for epirubicin or for 
amlodipine). The cells were further incubated for 12 hours, 
collected, and washed twice with PBS by centrifugation at 
2000 revolutions per minute (rpm) for 5 minutes. Cold lysis International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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buffer containing dithiothreitol was then added into the 
  collected cells and mixed homogeneously. The cells were 
incubated on ice for 60 minutes and then vortexed three or 
four times for 10 seconds each time. The cell lysates were then 
centrifuged at 10,000 rpm for 1 minute at 4°C. Finally, the 
supernatants were sucked off and transferred to new tubes on 
ice. The assay for caspase-9 was based on spectrophotomet-
ric detection of the chromophore p-nitroanilide (pNA) after 
cleavage from the labeled substrate LEHD-pNA. The pNA 
light emission was quantified using a microplate reader at 
405 nm. Caspase-9 activity was calculated with the formula: 
caspase-9 activity = (caspase-9 protein level of the treated 
cells)/(caspase-9 protein level of the control cells).
Caspase-3 activity was measured using the caspase-3 
colorimetric assay kit (Nanjing KeyGen Biotech Co, Ltd, 
Nanjing, China), and the procedure was the same as for 
measuring caspase-9 activity. The assay is based on spec-
trophotometric detection of the chromophore pNA after 
cleavage from the labeled substrate DEVD-pNA. The pNA 
light emission was quantified using a microplate reader at 
405 nm. Caspase-3 activity was calculated with the formula: 
caspase-3 activity = (caspase-3 protein level of the treated 
cells)/(caspase-3 protein level of the control cells).
In-vivo antitumor effects and TUNeL 
(terminal deoxynucleotidyl transferase 
dUTP nick end labeling) analysis
All animal experiments were adhered to the principles of 
care and use of laboratory animals and were approved by 
the Institutional Animal Care and Use Committee of Peking 
University. Female BALB/c nude mice (initially weighing 
14–16 g, Peking University Health Science Center) were 
divided into five groups (six in each). Cyclophosphamide 
was injected intraperitoneally into the mice at a dose of 2 mg 
per mouse per day for two consecutive days. Approximately 
2.0 × 107 MDR K562/ADR cells re-suspended in 200 µL of 
serum-free cell culture medium were subcutaneously injected 
into the right flanks of the nude mice. On day 7, 9, 11, 13, 
15, and 17 after inoculation, physiological saline, free epiru-
bicin (3 mg/kg), epirubicin liposomes (3 mg/kg   epirubicin), 
antiresistant epirubicin liposomes (3 mg/kg epirubicin plus 
1.2 mg/kg   amlodipine), and antiresistant epirubicin mito-
somes (3 mg/kg epirubicin plus 1.2 mg/kg amlodipine) were 
injected into mice via the tail vein. The tumor sizes of the 
mice were monitored once daily, and tumor volumes were 
calculated as length × width2 × 0.52 (mm3).27
Tumor-bearing mice were sacrificed on day 20 by cer-
vical dislocation. Tumor masses were carefully isolated, 
and fixed for analysis using TUNEL. An ApopTag plus 
peroxidase in-situ apoptosis detection kit (Intergen Co, Ltd, 
Burlington, MA) was used to visualize the cells with DNA 
fragmentation, as reported previously.28,29   Nonnecrotic 
zone was selected in the tumor section, and images were 
randomly selected under the light microscope. In the 
presence of apoptosis, the apoptotic cells manifested as 
brownish staining in the nuclei. At least 1000 tumor cells 
were counted, and the percentage of TUNEL-positive cells 
was determined.
statistics
Data are presented as means ± standard deviations. 
  One-way analysis of variance was used to determine sig-
nificance among groups, after which post-hoc tests with the 
  Bonferroni correction were used for comparison between 
individual groups. A value of P , 0.05 was considered to 
be significant.
Results
characterization of the mitosomes
For antiresistant epirubicin mitosomes, antiresistant 
  epirubicin liposomes, epirubicin liposomes, and amlodipine 
liposomes, the encapsulation efficiencies of epirubicin or 
amlodipine were all $90%. For antiresistant   epirubicin 
mitosomes, the modifying efficiency of dequalinium 
was approximately 70 µg/µmol lipids. For antiresistant 
  epirubicin mitosomes, antiresistant epirubicin liposomes, 
epirubicin liposomes, and amlodipine liposomes, the mean 
particle sizes were 109.2 ± 0.8, 107.8 ± 1.4, 113.7 ± 1.4, and 
112.6 ± 5.7 nm, respectively. The particle size distributions 
(PDI) were 0.196 ± 0.002, 0.222 ± 0.006, 0.253 ± 0.007, 
and 0.251 ± 0.026, respectively. The zeta potential values 
were 1.564 ± 0.370, 1.129 ± 0.223, 0.900 ± 0.450, and 
0.666 ± 0.169 mV , respectively.
For antiresistant epirubicin mitosomes, antiresistant 
epirubicin liposomes, and epirubicin liposomes in vitro, the 
release rates of epirubicin at 48 hours were 10.36% ± 0.19%, 
30.42% ± 0.97%, and 21.38% ± 0.14%, respectively 
(Figure 1A). For antiresistant epirubicin mitosomes, anti-
resistant epirubicin liposomes, and amlodipine liposomes 
in vitro, the release rates of amlodipine at 48 hours were 
24.41% ± 0.17%, 38.57% ± 0.63%, and 14.65% ± 0.22%, 
respectively (Figure 1B).
Figure 1C shows the TEM image of antiresistant epirubi-
cin mitosomes. Results showed that antiresistant epirubicin 
mitosomes were monodispersed and spherical with a diameter 
between 100 and 110 nm.International Journal of Nanomedicine 2011:6
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Figure 1 (A) In-vitro release rates (%) of epirubicin from epirubicin liposomes, 
amlodipine  liposomes,  anti-resistant  epirubicin  liposomes,  and  anti-resistant 
epirubicin mitosomes in PBs containing 10% FBs at 37°c. (B) In-vitro release rates 
(%) of amlodipine from epirubicin liposomes, amlodipine liposomes, anti-resistant 
epirubicin  liposomes,  and  anti-resistant  epirubicin  mitosomes  in  PBs  containing 
10%  FBs  at  37°c.  Data  are  presented  as  means  ±  standard  deviations  (n  = 3). 
(C) Transmission electron microscopy image of anti-resistant epirubicin mitosomes.
Note: scale bar = 100 nm.
Abbreviations: PBs, phosphate-buffered saline; FBs, fetal bovine serum.
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cytotoxicity
Figure 2Ai and Aii show the MTT assay results after 
  epirubicin alone or epirubicin plus amlodipine were applied 
to K562 cells and MDR K562/ADR cells, respectively. 
Epirubicin alone (0.05–2.0 µM) was effective in inhibiting 
the proliferation of K562 cells, showing a dose-dependent 
manner. After the addition of amlodipine (10 or 20 µM), the 
inhibitory rates of epirubicin (0.05–2.0 µM) to K562 cells 
were significantly increased, displaying an evident syner-
gistic effect. The inhibitory rates to MDR K562/ADR cells 
of epirubicin were ,20% at a concentration ranging from 
0.05 to 2.0 µM. After co-treating various concentrations 
of epirubicin (0.05–2.0 µM) with a fixed concentration of 
amlodipine (5.0, 10.0, or 20.0 µM), the survival rates of 
MDR K562/ADR cells were significantly reduced, com-
pared with those treated with epirubicin alone at the same 
concentration. The inhibiting effect was increased with 
the rise of amlodipine concentration, displaying a dose-
dependent manner.
Figure 2Bi and Bii depict the effects on the proliferation 
of K562 and MDR K562/ADR cells after applying 
free   epirubicin, free amlodipine, epirubicin liposomes, 
  amlodipine liposomes, antiresistant epirubicin liposomes, 
and antiresistant epirubicin mitosomes. Results showed that 
antiresistant epirubicin mitosomes exhibited the strongest 
inhibitory effect to the proliferation among all the groups in 
both K562 cells and MDR K562/ADR cells. The inhibiting 
effect to the cells was increased with the rise of epirubicin 
or amlodipine   concentration in antiresistant epirubicin 
  mitosomes,   displaying a dose-dependent manner.
Figure 2C shows the growth inhibition effect on K562 
and MDR K562/ADR cells of PBS-loaded mitosomes. 
The   survival rates of K562 and MDR K562/ADR cells 
after applying PBS-loaded mitosomes for 43 hours were 
87.10% ± 5.10% and 68.65% ± 9.14%, respectively, where 
the membrane components were equivalent to antiresistant 
epirubicin mitosomes loaded with 10 µM epirubicin.
Mitochondria-targeting by confocal assay
Figure 3A–F, M, G–L, and N represent the   confocal laser 
scanning microscopic images of K562 and MDR K562/
ADR cells after applying drugs to the cells for 1 hour at 
37°C and stained with MitoTracker Green,   respectively. 
Figure 3C–F and M represent the confocal laser   scanning 
microscopic images after applying free epirubicin, 
  epirubicin liposomes, antiresistant epirubicin liposomes, 
and antiresistant epirubicin mitosomes to K562 cells, 
respectively.   Similarly, Figure 3I–L and N denote the results 
after applying the above drugs to MDR K562/ADR cells, 
respectively.
In the images, mitochondria were seen as the green fluo-
rescent color stained by MitoTracker Green   (Figure 3B, Ci, 
Di, Ei, Fi, Mi; Figure 3H, Ii, Ji, Ki, Li, and Ni), and epirubi-International Journal of Nanomedicine 2011:6
Figure 2 (A) effects of free epirubicin, free amlodipine, or free epirubicin co-treated with free amlodipine on the viable rates of K562 (i) and MDr K562/ADr cells (ii) 
measured by microtiter tetrazolium assay. (B) effects of various formulations on the viable rates of K562 (i) and MDr K562/ADr cells (ii). (C) effects of phosphate-buffered 
saline-loaded mitosomes on the viable rates of K562 and K562/ADr cells.
Notes: aP , 0.05, versus free epirubicin; bP , 0.05, versus free epirubicin of various concentrations plus amlodipine (5.0 µM); cP , 0.05, versus free epirubicin of various 
concentrations plus amlodipine (10.0 µM); dP , 0.05, versus free amlodipine; eP , 0.05, versus epirubicin liposomes; fP , 0.05, versus amlodipine liposomes; gP , 0.05, versus 
epirubicin plus amlodipine liposomes; *the membrane components were comparable to those of anti-resistant epirubicin mitosomes at the designated concentration point 
but not containing drugs in the empty mitosomes. Data are presented as the means ± standard deviations (n = 3).
Abbreviation: MDr, multidrug resistant.
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cin from free epirubicin, epirubicin   liposomes,   antiresistant 
epirubicin liposomes, or antiresistant epirubicin mitosomes 
was shown as a red fluorescent color   (Figure 3Cii, Dii, Eii, 
Fii, and Mii; Figure 3Iii, Jii, Kii, Lii, and Nii). A bright 
yellow fluorescent color represented a   composition of red 
and green fluorescence, demonstrating that the liposomes 
containing epirubicin were co-localized into mitochondria 
(Figure 3Ciii, Diii, Eiii, Fiii, and Miii; Figure 3Iiii, Jiii, Kiii, 
Liii, and Niii).
The results show that free epirubicin,   epirubicin 
liposomes,  and  antiresistant  epirubicin  liposomes 
mostly distributed in the nucleus of the K562 cells and International Journal of Nanomedicine 2011:6
AB
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Figure 3 (A–F, M) Laser confocal fluorescence images of K562 cells incubated with various formulations for 1 hour at 37°C (magnification ×200 or ×600). (G–L, N) Laser 
confocal fluorescence images of MDR K562/ADR cells incubated with various formulations for 1 hour at 37°C (magnification ×200 or ×600). (A and G) Treated with PBs 
as a blank control. (B and H) Treated with PBs and stained with MitoTracker green. (C and I) Treated with free epirubicin (10 µM) and stained with MitoTracker green. 
(D and J) Treated with epirubicin liposomes (10 µM epirubicin) and stained with MitoTracker green. (E and K) Treated with anti-resistant epirubicin liposomes (10 µM 
epirubicin plus 10 µM amlodipine) and stained with MitoTracker green. (F, L, M and N) Treated with anti-resistant epirubicin mitosomes (10 µM epirubicin plus 10 µM 
amlodipine) and stained with MitoTracker green.
Notes: (i) green channel: MitoTracker green® (Invivogen corporation agent, Beijing, china) stained mitochondria. (ii) red channel: epirubicin. (iii) composite images of 
(i) and (ii). The bright yellow fluorescence in Fiii, Liii, Miii, and Niii shows that anti-resistant epirubicin mitosomes are co-localized into the mitochondria of both K562 and 
MDr K562/ADr cells, demonstrating that the anti-resistant epirubicin mitosomes are selectively accumulated into the mitochondria of both leukemia cells.
Abbreviations: MDr, multidrug resistant; PBs, phosphate-buffered saline.
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Figure 4 (A) caspase-9 activity in K562 (Ai and Bi) and MDr K562/ADr cells (Aii and Bii) induced by various formulations. (B) caspase-3 activity in K562 (Ai and Bi) 
and MDr K562/ADr cells (Aii and Bii) induced by various formulations.
Notes: Data are presented as means ± standard deviations (n = 3). aP , 0.05, versus the blank control; bP , 0.05, versus free epirubicin; cP , 0.05, versus free amlodipine; 
dP , 0.05, versus epirubicin liposomes; eP , 0.05, versus antiresistant epirubicin liposomes.
Abbreviation: MDr, multidrug resistant.
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MDR K562/ADR cells   (Figure 3D–E; Figure 3I–K). On 
the contrary, antiresistant epirubicin mitosomes selec-
tively accumulated into the mitochondria of both the 
K562 cells (Figure 3F and M) and MDR K562/ADR cells 
 ( Figure 3L and N).
caspase-9 and -3 activity
Figure 4A and B show the results of caspase-9 activity assays 
and caspase-3 activity assays in K562 cells and MDR K562/
ADR cells, respectively. Results from caspase-9 assay showed 
that the activity of caspase-9, in both K562 and MDR K562/
ADR cells, was significantly increased by antiresistant epiru-
bicin mitosomes, compared with that of control. The results in 
K562 cells indicated that the caspase-9 activity of K562 cells 
was increased after adding free epirubicin, free amlodipine, 
epirubicin liposomes, antiresistant epirubicin liposomes, or 
antiresistant epirubicin mitosomes. The caspase-9 activity of 
K562 cells after treating with antiresistant epirubicin mitosomes 
was the highest among all the treatment groups   (Figure 4Ai). 
The results in MDR K562/ADR cells indicated that the 
caspase-9 activity of MDR K562/ADR cells was increased 
after adding antiresistant epirubicin liposomes or antiresistant 
epirubicin mitosomes. The caspase-9 activity of MDR K562/
ADR cells was slightly higher after treating with antiresistant 
epirubicin mitosomes compared with that after treating with 
antiresistant epirubicin liposomes (Figure 4Aii).
Results from caspase-3 assay in K562 and MDR K562/
ADR cells showed a similar result to that of caspase-9 
 ( Figure 4Bi and Bii).
In-vivo antitumor effects  
and TUNeL analysis
The cancer masses appeared at the 5th or 6th day after MDR 
K562/ADR cells were inoculated in the nude mice.   Compared 
with the control group administered as physiological saline, 
the tumor growth was obviously inhibited in all treatment International Journal of Nanomedicine 2011:6
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Figure 5 (A) effect of anti-resistant epirubicin mitosomes on the MDr K562/
ADr xenografts in female nude mice. At the seventh, ninth, eleventh, thirteenth, 
fifteenth, and seventeeth days after inoculation, physiological saline, free epirubicin 
(3  mg/kg),  epirubicin  liposomes  (3  mg/kg  epirubicin),  anti-resistant  epirubicin 
liposomes  (3  mg/kg  epirubicin  plus  1.2  mg/kg  amlodipine),  and  anti-resistant 
epirubicin  mitosomes  (3  mg/kg  epirubicin  plus  1.2  mg/kg  amlodipine)  were 
given to mice via tail vein, respectively.  (B) Paraffin sections showing terminal 
deoxynucleotidyl  transferase-mediated  dUTP-biotin  nick  end-labeled  cells  in  the 
tumor tissues on the 20th day after inoculation of MDr K562/ADr cells in the 
female  nude  mice  (magnification  ×200).  Apoptotic  cells  (shown  by  arrowhead) 
are characterized by a dense staining of nuclei. The MDr K562/ADr xenografted 
mice were given intravenously with physiological saline as a blank control (i), free 
epirubicin (ii), epirubicin liposomes (iii), anti-resistant epirubicin liposomes (iv), and 
anti-resistant epirubicin mitosomes (v).
Notes: Data are presented as the means ± standard deviations (n = 6). aP , 0.05, 
versus physiological saline;  bP , 0.05, versus free epirubicin;  cP , 0.05, versus 
epirubicin liposomes; dP , 0.05, versus anti-resistant epirubicin liposomes.
Abbreviation: MDr, multidrug resistant.
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groups, but the antitumor effect varied. After giving 
  antiresistant epirubicin mitosomes, the tumor volumes from 
the 8th to the 13th day were significantly smaller compared 
with those after administering free epirubicin alone, and at 
the 20th day were significantly smaller compared with those 
after injecting free epirubicin alone, epirubicin liposomes, 
or antiresistant epirubicin liposomes. In comparison among 
groups, the rank order for antitumor effect in vivo was as 
follows: antiresistant epirubicin mitosomes . antiresistant 
epirubicin liposomes . epirubicin liposomes . free epiru-
bicin alone . physiological saline (the control) (Figure 5A). 
Results showed that the treatment of antiresistant epirubicin 
mitosomes resulted in a robust efficacy in reducing the 
tumor volume.
The TUNEL assay showed that the apoptotic percentages 
were 7.2% ± 0.8% for antiresistant epirubicin mitosomes 
(Figure 5Bv), 4.8% ± 1.0% for antiresistant epirubicin 
liposomes (Figure 5Biv), 3.0% ± 0.6% for epirubicin lipo-
somes (Figure 5Biii), and 2.0% ± 0.9% for free epirubicin 
(Figure 5Bii), compared with 0.5% ± 0.5% for control 
(Figure 5Bi).
Discussion
In the present study, the mitochondrial targeting antiresistant 
epirubicin liposomes named as the antiresistant epirubicin 
mitosomes are constructed by modifying dequalinium on 
their surface as a mitochondrial targeting agent.   Antiresistant 
epirubicin mitosomes show selective mitochondrial accumu-
lation behavior and induce apoptotic effect on the resistant 
human chronic myelogenous leukemia. Resistant human 
myeloid leukemia cells are well known to be resistant to a 
number of pro-apoptotic agents like anticancer drugs because 
of the overexpression of anti-apoptosis factors, including 
Bcr-Abl tyrosine kinase, Bcl-2, Bcl-xL, P-glycoprotein, 
or multidrug resistance protein.30–32 There is also a set of 
  pro-apoptosis genes expressed in leukemia cells which can 
be used as the target for chemotherapy. In the   membrane of 
cancer mitochondria, two kinds of apoptotic genes, namely 
apoptotic suppressing genes and pro-  apoptotic genes, 
are associated with the drug resistance of cancer cells.33 
Consequently, antiresistant epirubicin mitosomes were 
constructed for suppressing the anti-apoptosis genes and 
for activating the pro-apoptotic genes. The mitosomes 
were able to maintain the characteristics of the pegylated 
liposomes, including the long circulatory effect in the blood 
system.34 Therefore, antiresistant epirubicin mitosomes may 
provide a thorough approach for eliminating resistant and 
nonresistant tumors.
In the present study, cytotoxicity assays were performed 
on human chronic myelogenous leukemia K562 and MDR 
K562/ADR cells to evaluate the additive antiproliferative 
effects of amlodipine and the antiproliferative effect of anti-
resistant epirubicin mitosomes, respectively. Results indicated International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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that   epirubicin alone is effective in inhibiting the growth 
of   nonresistant K562 cells, but resistant to that of MDR 
K562/ADR cells. In the MDR K562/ADR cells, epirubicin in 
combination with amlodipine is effective in inhibiting the growth 
of MDR K562/ADR cells, indicating amlodipine was effective 
in reversing the resistance derived from the MDR K562/ADR 
cells. The reverse effect was increased with the rise in amlo-
dipine concentration, exhibiting a dose-dependent manner. In 
K562 cells, the synergistic inhibitory effects are observed after 
co-treating with epirubicin plus amlodipine, suggesting that 
amlodipine was effective in enhancing the antitumor effect 
of epirubicin. Compared with other controls, antiresistant 
epirubicin mitosomes exhibited the strongest anticancer effect 
in K562 or MDR K562/ADR cells. After applying antiresis-
tant epirubicin mitosomes, higher inhibition rates (60.5% in 
MDR K562/ADR cells) indicated that antiresistant epirubicin 
mitosomes were effective in inhibiting the proliferation of 
MDR K562/ADR cells in vitro. The reasons were as follows: 
(1) apoptotic inducer amlodipine could enhance anticancer 
efficacy of epirubicin and reverse the resistance of MDR 
K562/ADR cells when epirubicin and amlodipine were simul-
taneously incorporated into the   mitosomes; (2) antiresistant 
epirubicin mitosomes could enhance concentrations of the 
drugs accumulated in mitochondria by selectively accumulat-
ing into the mitochondria, which may enhance apoptosis of 
K562 and MDR K562/ADR cells.
Dequalinium is a “single-chain bala-amphiphile”35 with 
two charge centers separated at a relatively large distance. 
Such symmetric bola-like structures are well known from 
archaeal lipids, which usually consist of two glycerol back-
bones connected by two hydrophobic chains.36 Dequalinium 
is able to self-associate into mitochondriotropic cationic 
“bola-lipid”-based vesicles, named DQAsomes.23,37 The 
DQAsomes have been developed for transport of drugs 
and DNA to mitochondria in living cells.38,39 In the pres-
ent study, dequalinium is modified on the antiresistant 
epirubicin mitosomes with the same intention for targeting 
mitochondria. Mitochondria-targeting studies of antiresis-
tant epirubicin mitosomes were performed on leukemia 
K562 and MDR K562/ADR cells using the confocal laser 
fluorescent microscopy technique. Results demonstrated 
that antiresistant epirubicin mitosomes were able to be co-
localized into mitochondria of K562 and MDR K562/ADR 
cells, indicating that antiresistant epirubicin mitosomes were 
selectively accumulated into mitochondria of both leukemia 
cells, respectively.
After treating with drugs, cancer cells may be killed 
by injurious agents or by inducing programmed cell 
death (apoptosis), which may be generated by external signals 
(death   receptor-mediated) or by internal signals (mitochondria-
mediated). Activation of the effector cascade differs between 
extrinsic and intrinsic pathways. In the intrinsic pathways 
mediated by mitochondria, the apoptotic inducer increases the 
permeability of the outer membrane, causes cytochrome c to 
be released, then results in activation of caspase-9 and subse-
quent effector caspases, such as caspase-3, and finally leads 
to apoptosis of cells.40,41 In the present study, caspase-9 and 
caspase-3 activity were measured to discover whether these 
pathways were involved in the process of apoptosis initiated 
by antiresistant epirubicin mitosomes. Results showed that, 
in both K562 and MDR K562/ADR cells, caspase-9 and   
caspase-3 activity were most evidently increased after applying 
antiresistant epirubicin mitosomes. It was then postulated that 
antiresistant epirubicin mitosomes could enter into the cancer 
cells, target mitochondria to induce the PT pore opening, and 
thereby result in the swelling of mitochondria and then spill-
age of cytochrome c. The released cytochrome c bound with 
Apaf-1 in the cytosol, and changed conformation of Apaf-1, 
leading to subsequent bindings with pro-caspase-9 and dATP. 
As a result, caspase-9 was cleaved, thus initiating a cascade of 
caspase activation like caspase-3 and leading to apoptosis of 
resistant or nonresistant leukemia cells.
Antitumor activities and apoptosis studies in vivo were 
performed on MDR K562/ADR cell xenografts in female 
BALB/c nude mice. Results showed that the   antitumor 
effect of antiresistant epirubicin mitosomes was the most 
effective, compared with free epirubicin, epirubicin lipo-
somes, or antiresistant epirubicin liposomes. TUNEL analysis 
demonstrated that antiresistant epirubicin mitosomes exerted 
favorable inducing apoptotic effect compared with other 
  controls. The possible reasons may be as follows: (1) amlo-
dipine as an apoptotic inducer could enhance anticancer 
efficacy and reverse the resistance in vivo; (2) the mitosomes 
as stealth liposomes with smaller particle size around 100 nm 
were able to extravasate through the “pores” of the capil-
lary endothelium of tumor vasculature in a more efficient 
manner, resulting in an increased accumulation of those 
mitosomes in the interstitial spaces of tumor tissues;42,43 (3) 
the mitosomes as stealth liposomes exhibited prolonged half 
lives and sustained drug-release profiles in vivo, which could 
improve antitumor activity;44 and (4) the mitochondrial genes 
could be regulated by apoptotic inducer amlodipine, which 
was selectively delivered to mitochondria by antiresistant 
epirubicin mitosomes.
In conclusion, a new kind of cancer mitochondria-specific 
drug-loaded liposome was designed, antiresistant   epirubicin International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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mitosomes, which could provide a complete solution to 
the intrinsic MDR of cancers. Antiresistant epirubicin 
mitosomes could selectively accumulate into mitochondria 
of cancer cells and initiate the intrinsic pathway mediated 
by mitochondria through inducing the PT pore opening, 
resulting in release of cytochrome c, followed by activating 
caspase-9, and subsequently the effector caspase-3. In vitro, 
antiresistant epirubicin mitosomes were effective in inhibit-
ing the proliferation of both K562 and MDR K562/ADR 
cells, and in reversing drug resistance of MDR K562 cells. 
In vivo, antiresistant epirubicin mitosomes had the enhanced 
antitumor effects, and inducing apoptotic effects in the MDR 
K562/ADR xenografts. Therefore, antiresistant epirubicin 
mitosomes may provide a promising strategy for improving 
therapeutic efficacy in the resistant human leukemia.
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